ARTICLE | Company News
BioImage, TopoTarget deal
January 2, 2006 8:00 AM UTC
TOPO acquired from BioImage a preclinical cancer program that includes about 100 diphenyl ox-indole-2-one compounds, which act via the mTOR signaling pathway. TOPO plans to start Phase I testing of t...